Update on Precision Medicine in Breast Cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Precision medicine has revolutionized treatment for various cancers, improving outcomes for diseases like EGFR-mutated lung cancer and BRAF-mutated melanoma.
• Despite early target identification (ER, HER2), precision medicine in breast cancer is less advanced compared to other tumor types.
• While progress exists for hormone-receptor-positive and HER2-positive breast cancers, triple-negative breast cancer (TNBC) faces challenges due to molecular heterogeneity and a lack of validated targets.

Purpose of the Study:

• To review recent technological and therapeutic advancements in precision medicine for breast cancer.
• To identify persistent challenges hindering the widespread application of precision medicine in breast cancer.
• To highlight ongoing efforts to make precision medicine accessible to all breast cancer patients.

Main Methods:

• Review of current literature on precision medicine in oncology.
• Analysis of technological innovations impacting targeted cancer therapy.
• Examination of clinical trial data and research strategies for breast cancer.

Main Results:

• Significant advancements in targeted therapies for ER-positive and HER2-positive breast cancers have been achieved.
• Molecular heterogeneity and the absence of reliable targets in triple-negative breast cancer (TNBC) present major obstacles.
• New technologies and ongoing research are crucial for developing effective precision treatments for all breast cancer subtypes.

Conclusions:

• Precision medicine holds immense promise for breast cancer, but TNBC requires further dedicated research.
• Overcoming molecular heterogeneity and identifying novel targets are critical for advancing breast cancer precision therapy.
• Continued innovation in technology and targeted treatments is essential to realize the full potential of precision medicine for every breast cancer patient.